Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Radboudumc at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Radboudumc brings 2 presentations to ASH 2026 in New Orleans. Its program covers glycans as a cause of and therapeutic target in myeloid cancers, and calreticulin mutations in inherited high platelet counts. It also joins advice for trainees moving into faculty roles.

OrganizationASH 2026 Attendance
Radboudumc
Nijmegen, Netherlands
Hospitals & cancer centres
Academic medical centre of Radboud University in Nijmegen, the Netherlands.
Talk
Sun Dec 13
4:30pm–5:45pm
Glycans in the Pathogenesis and as a Therapeutic Target in Myeloid Malignancies
How sugar chains on growth factor receptors shape their function, drive chemotherapy resistance and immune evasion, and could be drug targets in myeloid cancers.
Blood biology

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Radboudumc

Tell us what you sell and we’ll find the people at Radboudumc most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction